BRONCHENOLO TOSSE ® Dextromethorphan

BRONCHENOLO TOSSE ® is a drug based on dextromethorphan bromidhydrate

THERAPEUTIC GROUP: Cough sedatives

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications BRONCHENOLO TOSSE ® Dextromethorphan

BRONCHENOLO TOSSE ® is used in the symptomatic treatment of cough.

Mode of action BRONCHENOLO TOSSE ® Dextromethorphan

BRONCHENOLO TOSSE ® is a drug based on dextromethorphan, a synthetic morphine derivative without the typical opiate activity.

Taken orally, dextromethorphan is rapidly and effectively absorbed by the mucosa of the gastrointestinal tract, and following a first-pass metabolism, distributed among the various tissues, where it carries out its biological activity.

More precisely, at the central nervous level this active principle, interacting with non-opioid receptors, increases the concentrations of Serotonin, thus carrying out a modest sedative action, concentrated mainly at the level of the cough center.

The depressing activity of the cough, effective both in the course of cooling syndromes and in the course of allergic pathologies, lasts several hours, after which, after a further hepatic metabolism, the dextromethorphan, in the form of different catabolites, is eliminated through the urine.

Studies carried out and clinical efficacy

DESTROMETORPHAN IN YOUTH INTOXICATIONS

Arch Med Sadowej Kryminol. 2012 Jul-Sep; 62 (3): 197-202.

Case report that denounces the ever-increasing number of cases in the youth population, of intoxications associated with the abuse of over-the-counter drugs containing centrally acting substances, with euphoric or sedative power such as dextromethorphan.

DESTROMETORPHAN IN NIGHTLIFE

Indian J Pediatr. 2013 Apr 17.

Work demonstrating the inability of dextromethorphan to quell the night cough in small patients aged 1 to 12 years with infectious diseases of the upper respiratory tract.

Probably this failure is determined by the spontaneous resolution of the cough at night in this type of pathology

DESTROMETORPHAN AND CYCLOSPORIN IN THE TREATMENT OF THE ENSAFALOPATHY

Pediatr Neurol. 2013 Mar; 48 (3): 200-5. doi: 10.1016 / j.pediatrneurol.2012.11.003.

Interesting study that demonstrates how the combined treatment between dextromethorphan and cyclosporine A can be effective in the treatment and prevention of encephalopathy, reducing the incidence of serious clinical complications.

Method of use and dosage

BRONCHENOLO TOSSE ®

154 mg syrup of dextromethorphan bromidhydrate per 100 ml of syrup.

Dextromethorphan bromide hydrochloric 7.5 mg tablets.

The effective therapeutic dosages in adults generally fall within the 60 mg daily of Dextromethorphan bromidhydrate divided into 3-4 assumptions.

Halved dosages are instead used in children, for whom however medical supervision would be appropriate in any case.

Therapy should not last longer than 5-7 days of treatment without consulting with your doctor.

Warnings BRONCHENOLO TOSSE ® Dextromethorphan

In order to guarantee a good therapeutic result and minimize potential side effects, it would be advisable for the patient to consult the doctor before taking BRONCHENOLO TOSSE ®.

In fact the use of this drug should be done with particular caution in patients suffering from chronic or persistent respiratory pathologies, liver pathologies and kidney pathologies, for which, the variation of the pharmacokinetic characteristics of Dextromethorphan, could determine the onset of potential side effects.

BRONCHENOLO TOSSE ® contains sucrose, therefore its use is contraindicated in patients suffering from saccharase enzyme deficiency, fructose intolerance and glucose-galactose malabsorption.

It is advisable to keep the medicine out of the reach of children.

BRONCHENOLO TOSSE ® could cause drowsiness, making it dangerous to drive vehicles or use machinery.

PREGNANCY AND BREASTFEEDING

Given the absence of studies able to characterize the safety profile of Dextromethorphan for the health of the unborn child, it would be advisable to avoid the use of this drug during pregnancy and in the subsequent period of breastfeeding.

Interactions

In order to avoid the incidence of potential side effects, it would be appropriate for patients on therapy with monoamine oxidase inhibitors, serotonin reuptake inhibitors, tricyclic antidepressants, inhibitors or inducers of cytochromial enzymes and alcohol, to avoid the simultaneous intake of BRONCHENOL COUGH ®.

Contraindications BRONCHENOLUS Cough ® Dextromethorphan

The use BRONCHENOLO TOSSE ® is contraindicated in patients suffering from severe liver and kidney diseases, from respiratory pathologies with a high risk of respiratory insufficiency and in the course of therapy with antidepressant MAO inhibitors.

Evidently the use of this drug is contraindicated also in patients hypersensitive to the active ingredient or to one of its excipients.

Undesirable effects - Side effects

The use of BRONCHENOLO TOSSE ® could cause, fortunately only rarely, drowsiness, nausea, vomiting, abdominal pain and dizziness.

There are definitely fewer neurological adverse reactions associated with the disproportionate increase in Serotonin, known together with the name Serotonin syndrome.

Even more rare are the adverse reactions associated with hypersensitivity to the active ingredient.